10x Genomics (TXG) News Today

10x Genomics (NASDAQ:TXG) Stock Price Up 6.4%

Edgestream Partners L.P. bought a new stake in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 35,718 shares of the company's stock, valued at approximately

Canaccord Genuity Group lowered their target price on 10x Genomics from $50.00 to $32.00 and set a "buy" rating for the company in a research note on Tuesday.

Jefferies Financial Group raised 10x Genomics from a "hold" rating to a "buy" rating and set a $24.00 target price on the stock in a report on Monday.

Bank of America lowered their target price on 10x Genomics from $36.00 to $25.00 and set a "neutral" rating on the stock in a research note on Thursday.

JPMorgan Chase & Co. cut shares of 10x Genomics from an "overweight" rating to a "neutral" rating and lowered their price target for the company from $40.00 to $20.00 in a report on Thursday.

Life sciences company Illumina Inc. (NASDAQ: ILMN) stock surged over 10% following its announcement of the acquisition of Fluent Biosciences.

Susquehanna Fundamental Investments LLC bought a new stake in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 75,619 shares of the company's stock, valued at app

Quantbot Technologies LP acquired a new stake in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 78,341 shares of the company's stock, valued at approximately $2,940,000. Qua

10x Genomics (NASDAQ:TXG) Shares Gap Up to $16.99

10x Genomics (NASDAQ:TXG) Stock Price Up 7.3%

Deutsche Bank Aktiengesellschaft lowered shares of 10x Genomics from a "buy" rating to a "hold" rating and decreased their price target for the company from $55.00 to $25.00 in a research note on Wednesday.

10x Genomics (NASDAQ:TXG) Shares Down 2.9% After Analyst Downgrade

Shares of 10x Genomics, Inc. (NASDAQ:TXG - Get Free Report) have earned a consensus rating of "Hold" from the thirteen analysts that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and six have as

Mirae Asset Global Investments Co. Ltd. lifted its position in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 264.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 319,287 shares of the com

Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 58.6% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,621,778 shares of the company's stock after purchasing an add

10x Genomics (NASDAQ:TXG) Trading Up 3.7%

Barclays lowered their price target on shares of 10x Genomics from $36.00 to $24.00 and set an "overweight" rating for the company in a report on Friday.

10x Genomics (NASDAQ:TXG) Reaches New 1-Year Low at $18.39

Vanguard Group Inc. grew its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 1.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 9,011,332 shares of the company's stock after buying an additional 107,815 shar

10x Genomics (NASDAQ:TXG) Shares Gap Down to $19.88

10x Genomics (NASDAQ:TXG) Reaches New 52-Week Low at $19.29

10x Genomics, Inc. (NASDAQ:TXG - Get Free Report) has received an average rating of "Moderate Buy" from the thirteen ratings firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and eight ha

10x Genomics (NASDAQ:TXG) Sets New 1-Year Low at $20.97

Brown Capital Management LLC boosted its position in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 14.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,527,297 shares of the company's stock after acquiring an additional

SRS Investment Management LLC decreased its stake in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 34.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 683,893 shares of the company's stock after se

Venrock Management VI LLC acquired a new position in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 2,106,757 shares of the company's stock, valued at a

Freshford Capital Management LLC purchased a new stake in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 305,798 shares of the company's stock, valued at approx

Armistice Capital LLC bought a new position in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 92,000 shares of the company's stock, valued at approximately $5,148,000.

10x Genomics (NASDAQ:TXG) Sets New 1-Year Low at $21.29

Sands Capital Management LLC reduced its position in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 9.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,590,145 shares of the company's stock after selling 395,325 shares

Norges Bank purchased a new stake in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 647,996 shares of the company's stock, valued at approxima

Decheng Capital LLC bought a new stake in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 359,554 shares of the company's stock, valued at approximately $2